Effects of the nitrone radical scavengers PBN and S-PBN on in vivo trapping of reactive oxygen species after traumatic brain injury in rats.
In previous studies, the authors showed that the nitrone radical scavenger alpha-phenyl-N- tert -butyl nitrone (PBN) and its sulfo-derivative, 2-sulfo-phenyl-N- tert -butyl nitrone (S-PBN), attenuated cognitive disturbance and reduced tissue damage after traumatic brain injury (TBI) in rats. In the current study, the production of reactive oxygen species (ROS) after TBI was monitored with microdialysis and the 4-hydroxybenzoic acid (4-HBA) trapping method. A single dose of PBN (30 mg/kg) or an equimolar dose of S-PBN (47 mg/kg) was administered intravenously 30 minutes before a controlled cortical contusion injury in rats. Plasma and brain tissue drug concentrations were analyzed at the end of the microdialysis experiment (3 hours after injury) and, in a separate experiment with S-PBN, at 30 and 60 minutes after injury. Traumatic brain injury caused a significant increase in ROS formation that lasted for 60 minutes after the injury as evidenced by increased 3,4-dihydroxybenzoic acid (3,4-DHBA) concentrations in the dialysate. PBN and S-PBN equally and significantly attenuated the posttraumatic increase in 3,4-DHBA formation. High PBN concentrations were found bilaterally in brain tissue up to 3 hours after injury. In contrast, S-PBN was rapidly cleared from the circulation and was not detectable in brain at 30 minutes after injury or at any later time point. The results suggest that scavenging of ROS after TBI may contribute to the neuroprotective properties observed with nitrone spin-trapping agents. S-PBN, which remained undetectable even in traumatized brain tissue, reduced ROS production to the same extent as PBN that readily crossed the blood-brain barrier. This finding supports an important role for ROS production at the blood-endothelial interface in TBI.
Marklund
N
N
Department of Neuroscience, Neurosurgery, Uppsala University Hospital, Sweden.
Lewander
T
T
Clausen
F
F
Hillered
L
L
D000818:Animals; D001557:Benzenesulfonates / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D001812:Blood-Brain Barrier; D001930:Brain Injuries / Q000188:drug therapy* / Q000378:metabolism; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D062385:Hydroxybenzoates / Q000378:metabolism; D008297:Male; D017551:Microdialysis; D018696:Neuroprotective Agents / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D009589:Nitrogen Oxides / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics*; D010226:Parabens / Q000493:pharmacokinetics; D010296:Parietal Lobe / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D017382:Reactive Oxygen Species / Q000378:metabolism
D001557:Benzenesulfonates; D003497:Cyclic N-Oxides; D016166:Free Radical Scavengers; D062385:Hydroxybenzoates; D018696:Neuroprotective Agents; D009589:Nitrogen Oxides; D010226:Parabens; D017382:Reactive Oxygen Species; C094272:N-tert-butyl-(2-sulfophenyl)nitrone; C009091:protocatechuic acid; C029217:phenyl-N-tert-butylnitrone; C038193:4-hydroxybenzoic acid